Characteristics of Immune Response to Tumor‐Associated Antigens and Immune Cell Profile in Patients With Hepatocellular Carcinoma
- 13 August 2018
- journal article
- research article
- Published by Wolters Kluwer Health in Hepatology
- Vol. 69 (2) , 653-665
Abstract
Host antitumor immune responses may be different between hepatocellular carcinoma (HCC) caused by metabolic disorders and HCC associated with hepatitis virus infection. In this study, we examined the immune response of tumor‐associated antigen (TAA)–specific T cells and immune cell profile in patients with HCC separated by cause. Thirty‐two patients with hepatitis B virus (HBV)–related HCC, 42 patients with hepatitis C virus–related HCC, and 18 patients with nonalcoholic steatohepatitis (NASH)–related HCC were analyzed. The frequencies of TAA‐specific T cells, the expression levels of surface markers on each immune cell, and the expression of each TAA in HCC tissue were measured. The immune response to TAA and immune cell profile were markedly different among the three groups. The immune response to TAA in the NASH‐related HCC group was weaker than the responses in the other two groups. In patients with NASH‐related HCC, the frequencies of effector regulatory T cells (eTregs) and cluster of differentiation 8–positive (CD8+) T cells strongly expressing cytotoxic T‐lymphocyte antigen (CTLA)‐4 were high. The frequency of CD8+ T cells strongly expressing programmed cell death 1 was the highest in patients with HBV‐related HCC. Among these immune cell profiles, the frequencies of C‐X‐C motif chemokine receptor 3+ eTregs and CTLA‐4+CD8+ T cells were inversely correlated with the strength of the TAA‐specific T‐cell immune response, and the restoration of TAA‐specific T‐cell responses by anti‐CTLA‐4 antibody was observed. Conclusion : The immune response to TAA were markedly different among the three groups, and a correlation with the immune cell profile was observed, suggesting that development of immunotherapy based on the etiology of HCC may lead to more effective treatment outcomes.Keywords
Funding Information
- Ministry of Education, Culture, Sports, Science and Technology (16K15425)
This publication has 36 references indexed in Scilit:
- Phase I Trial of a Glypican-3–Derived Peptide Vaccine for Advanced Hepatocellular Carcinoma: Immunologic Evidence and Potential for Improving Overall SurvivalClinical Cancer Research, 2012
- Comparative analysis of various tumor-associated antigen-specific t-cell responses in patients with hepatocellular carcinomaHepatology, 2011
- Sorafenib in Advanced Hepatocellular CarcinomaNew England Journal of Medicine, 2008
- Detection of novel cancer‐testis antigen‐specific T‐cell responses in TIL, regional lymph nodes, and PBL in patients with esophageal squamous cell carcinomaCancer Science, 2008
- Identification of HLA-A24-restricted epitopes with high affinities to Hsp70 using peptide arraysJournal of Bioscience and Bioengineering, 2008
- Cytotoxic T cell responses to human telomerase reverse transcriptase in patients with hepatocellular carcinoma†Hepatology, 2006
- Identification of HLA-A2- or HLA-A24-Restricted CTL Epitopes Possibly Useful for Glypican-3-Specific Immunotherapy of Hepatocellular CarcinomaClinical Cancer Research, 2006
- Identification of α‐fetoprotein‐derived peptides recognized by cytotoxic T lymphocytes in HLA‐A24+ patients with hepatocellular carcinomaInternational Journal of Cancer, 2005
- Identification of an epitope from the epithelial cell adhesion molecule eliciting HLA‐A*2402‐restricted cytotoxic T‐lymphocyte responsesTissue Antigens, 2004
- Identification of HLA-A24-Restricted CTL Epitope from Cancer-Testis Antigen, NY-ESO-1, and Induction of a Specific Antitumor Immune ResponseClinical Cancer Research, 2004